Medical Condition News

RSS

AMGA honors Boehringer Ingelheim with Distinguished Corporate Partner Award

The American Medical Group Association announced today that it will present the AMGA Distinguished Corporate Partner Award on April 16 to Boehringer Ingelheim Pharmaceuticals at its 2011 Annual Conference, April 13-16 at the Gaylord National.

15 Apr 2011

FEN1 enzyme might serve as anti-cancer therapy target

An enzyme essential for DNA replication and repair in humans works in a way that might be exploited as anti-cancer therapy, say researchers at The Scripps Research Institute and Lawrence Berkeley National Laboratory.

15 Apr 2011

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn.

15 Apr 2011

New treatment improves immune function in 13-year-old with Wiskott-Aldrich syndrome

In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease.

15 Apr 2011

Varian Medical Systems launches new brachytherapy applicator

Varian Medical Systems is introducing a new brachytherapy applicator for treating endometrial cancer patients after a hysterectomy. The Capri applicator, aimed at increasing patient comfort and allowing clinicians to better sculpt the radiotherapy dose, is being exhibited this week at the annual American Brachytherapy Society meeting in San Diego.

15 Apr 2011

Investigational Alzheimer's compounds may treat neuropathies

Drugs already in development to treat Alzheimer's disease may eventually be tapped for a different purpose altogether: re-growing the ends of injured nerves to relieve pain and paralysis.

15 Apr 2011

Halozyme announces Aspart-PH20 study results in type 1 diabetes

Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.

15 Apr 2011

Early recognition of oral cancer symptoms

For decades, the incidence of oral cancer has remained nearly constant, partly because it can be difficult to detect. However, during April, Oral Cancer Awareness Month, Western Dental Services, Inc., is joining the national effort to support early recognition of oral cancer symptoms.

15 Apr 2011

Scientists identify novel small molecules that block human tumor cell growth

Researchers from the Cancer Institute at NYU Langone Medical Center have identified three novel small molecules that interrupt a crucial cellular communication pathway that regulates many aspects of development and cancer.

15 Apr 2011

Pharmacy costs for multiple sclerosis patients increase at a faster rate than medical costs

Analysis of direct pharmacy and medical costs for patients with multiple sclerosis (MS) showed pharmacy costs are increasing at a slightly faster rate than medical costs, but new MS medications are expected to shift the majority of the direct health cost burden to pharmacy, according to a new study by Prime Therapeutics (Prime). The study will be presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn.

15 Apr 2011

Study: 30% of patients with TBI more likely to suffer from depression

Vanderbilt researchers conducting an extensive analysis of studies on traumatic brain injury, report today that 30 percent of TBI patients, or approximately 360,000 patients each year, will also suffer from depression after their injury.

15 Apr 2011

Treatment of vascular risk factors may lower risk of Alzheimer's disease

Treating high blood pressure, high cholesterol, diabetes and other vascular risk factors may help lower the risk of Alzheimer's disease in people who already show signs of declining thinking skills or memory problems. The research is published in the April 13, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

15 Apr 2011

Acute high-fat diets can protect against heart attack

Approximately one million Americans suffer a heart attack each year of which some 400,000 attacks are fatal. A key cause of heart attacks is atherosclerosis, a process in which cholesterol builds up in the arteries and impedes the ability of the blood to flow to our most vital organ.

15 Apr 2011

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.

15 Apr 2011

Donor-specific antibodies may accelerate arteriosclerosis after kidney transplantation

Kidney transplant recipients who develop antibodies in response to receiving new organs can develop accelerated arteriosclerosis, or narrowing of the arteries that supply blood to the kidney, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that arteriosclerosis resulting from such donor-specific antibodies may play an important role in organ rejection following transplantation.

15 Apr 2011

Researchers pinpoint new approach that can treat pediatric leukemia

A Loyola University Health System study points to a promising new approach to treating an aggressive and usually fatal leukemia in babies.

15 Apr 2011

GSK announces safety profile of orlistat and alli

GlaxoSmithKline (GSK) is committed to ensuring that consumers and physicians understand the safety profile of orlistat and alli. alli is safe and effective when used as directed. Orlistat is minimally absorbed in the blood and works locally in the gastro-intestinal tract. GSK continues to proactively monitor for the safety of orlistat and share all relevant information with regulatory agencies.

15 Apr 2011